OptiNose, Inc. (OPTN): Price and Financial Metrics
GET POWR RATINGS... FREE!
OPTN POWR Grades
- OPTN scores best on the Growth dimension, with a Growth rank ahead of 78.3% of US stocks.
- OPTN's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- OPTN ranks lowest in Momentum; there it ranks in the 5th percentile.
OPTN Stock Summary
- OptiNose Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 2.55% of US listed stocks.
- OPTN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 97.96% of US stocks.
- OptiNose Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -31.49%, greater than the shareholder yield of only 8.26% of stocks in our set.
- Stocks that are quantitatively similar to OPTN, based on their financial statements, market capitalization, and price volatility, are KODK, ENSV, SIEN, HNGR, and MCF.
- OPTN's SEC filings can be seen here. And to visit OptiNose Inc's official web site, go to www.optinose.com.
OPTN Stock Price Chart Interactive Chart >
OPTN Price/Volume Stats
|Current price||$3.67||52-week high||$10.00|
|Prev. close||$3.62||52-week low||$2.80|
|Day high||$3.70||Avg. volume||383,565|
|50-day MA||$3.38||Dividend yield||N/A|
|200-day MA||$3.92||Market Cap||194.92M|
OptiNose, Inc. (OPTN) Company Bio
OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.
OPTN Latest News Stream
|Loading, please wait...|
OPTN Latest Social Stream
View Full OPTN Social Stream
Latest OPTN News From Around the Web
Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.
Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists, today announced that the publication of a new stepped-care treatment algorithm in the International Forum of Allergy & Rhinology, "Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps," recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatm
YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event. About OptinoseOptinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follo...
OptiNose (OPTN) has added ~13.0% in the post-market after the company disclosed a purchase of~34K common stock by the company’s chief commercial officer, Victor M Clavelli.With the purchase of shares at $3.06 apiece Clavelli has raised its stake in the company to ~142.3K. The transaction is the first insider deal recorded at OptiNose for the...
OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2021, and provided operational updates. “XHANCE net revenues increased 55% in the first quarter of 2021 compared to first quarter 2020,” stated CEO Peter Miller. “We believe this is strong growth, particularly in the context of the continuing impact of the COVID-19 pandemic on the number of patients visiting physician o...
OPTN Price Returns